Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12935-022-02621-y.

Title:
Identification of icaritin derivative IC2 as an SCD-1 inhibitor with anti-breast cancer properties through induction of cell apoptosis | Cancer Cell International
Description:
Background Breast cancer is the most common malignancy affecting women, yet effective targets and related candidate compounds for breast cancer treatment are still lacking. The lipogenic enzyme, stearoyl-CoA desaturase-1 (SCD1), has been considered a potential target for breast cancer treatment. Icaritin (ICT), a prenylflavonoid derivative from the Traditional Chinese Medicine Epimedii Herba, has been reported to exert anticancer effects in various types of cancer. The purpose of the present study was to explore the effect of the new ICT derivative, IC2, targeting SCD1 on breast cancer cells and to explore the specific mechanism. Methods Immunohistochemistry and semiquantitative evaluation were performed to detect the expression level of SCD1 in normal and tumor samples. Computer-aided drug design (CADD) technology was used to target SCD1 by molecular docking simulation, and several new ICT derivatives were prepared by conventional chemical synthesis. Cell viability was evaluated by an MTT assay and dead cell staining. SCD1 expression in cancer cells was determined by Western blot and qRT-PCR analyses. The enzymatic activity of SCD1 was evaluated by detecting the conversion rate of [d31] palmitic acid (PA) using Gas chromatography-mass spectrometry (GC–MS). DAPI staining, flow cytometry and Western blot were used to detect cell apoptosis. Mitochondrial membrane potential and reactive oxygen species (ROS) assays were used to determine cell mitochondrial function. Lentiviral transduction was utilized to generate SCD1-overexpressing cell lines. Results We found that SCD1 was overexpressed and correlated with poor prognosis in breast cancer patients. Among a series of ICT derivatives, in vitro data showed that IC2 potentially inhibited the viability of breast cancer cells, and the mechanistic study revealed that IC2 treatment resulted in ROS activation and cellular apoptosis. We demonstrated that IC2 inhibited SCD1 activity and expression in breast cancer cells in a dose-dependent manner. Moreover, SCD1 overexpression alleviated IC2-induced cytotoxicity and apoptosis in breast cancer cells. Conclusions The new ICT derivative, IC2, was developed to induce breast cancer cell apoptosis by inhibiting SCD1, which provides a basis for the development of IC2 as a potential clinical compound for breast cancer treatment.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, scd, cells, cell, breast, expression, pubmed, article, apoptosis, ict, google, scholar, mcf, fig, cas, treatment, data, effect, activity, acid, staining, china, results, mitochondrial, cat, control, potential, ros, fatty, protein, high, central, inhibition, significantly, effects, derivatives, wang, icaritin, compared, viability, icinduced, usa, reduced, concentrations, anticancer, study, samples, flow, cytometry, clinical,

Topics {✒️}

affecting mir-208a-5p-daam1-rhoa axis annexin v-fitc/pi staining kaplan–meier plotter analysis guo-sheng wu gas chromatography-mass spectrometry kaplan–meier survival plots chun-lei tang computer-aided drug design stearoyl-coa desaturase plays stearoyl-coa–binding sites stearoyl-coa–binding pocket extracellular signal-regulated kinase lung cancer-initiating cells endoplasmic reticulum-bound enzyme hui-lian che il-6/jak2/stat3 pathway kaplan–meier plotter ic2-induced cell apoptosis article download pdf icaritin-induced immunomodulatory efficacy fatty acid-induced lipotoxicity annexin v-fitc virus-related hepatocellular carcinoma live/dead assay showed scd1-dependent cell death anti-breast cancer properties egfr/pi3k/akt signals large-scale survival data ic2-induced antiproliferation effect ten-year survival rate egfr-targeting cancer therapy survival analysis showing viable scd1-overexpressing cells scd1-overexpression vector carries stearoyl-coa desaturase-1 stearoyl-coa desaturase 1 nanjing spring&autumn biotech dcfh-da fluorescent probe quantitative real-time pcr minimized molecule-docked complexes cell death induced yi-yuan jin monounsaturated fatty acids related subjects cell cycle arrest surpassed lung cancer human stearoyl–coenzyme human stearoyl-coenzyme apoptosis detection kit induces cell apoptosis

Questions {❓}

  • Lipid desaturation - the next step in targeting lipogenesis in cancer?
  • Mitochondrion: a common organelle for distinct cell deaths?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Identification of icaritin derivative IC2 as an SCD-1 inhibitor with anti-breast cancer properties through induction of cell apoptosis
         description:Breast cancer is the most common malignancy affecting women, yet effective targets and related candidate compounds for breast cancer treatment are still lacking. The lipogenic enzyme, stearoyl-CoA desaturase-1 (SCD1), has been considered a potential target for breast cancer treatment. Icaritin (ICT), a prenylflavonoid derivative from the Traditional Chinese Medicine Epimedii Herba, has been reported to exert anticancer effects in various types of cancer. The purpose of the present study was to explore the effect of the new ICT derivative, IC2, targeting SCD1 on breast cancer cells and to explore the specific mechanism. Immunohistochemistry and semiquantitative evaluation were performed to detect the expression level of SCD1 in normal and tumor samples. Computer-aided drug design (CADD) technology was used to target SCD1 by molecular docking simulation, and several new ICT derivatives were prepared by conventional chemical synthesis. Cell viability was evaluated by an MTT assay and dead cell staining. SCD1 expression in cancer cells was determined by Western blot and qRT-PCR analyses. The enzymatic activity of SCD1 was evaluated by detecting the conversion rate of [d31] palmitic acid (PA) using Gas chromatography-mass spectrometry (GC–MS). DAPI staining, flow cytometry and Western blot were used to detect cell apoptosis. Mitochondrial membrane potential and reactive oxygen species (ROS) assays were used to determine cell mitochondrial function. Lentiviral transduction was utilized to generate SCD1-overexpressing cell lines. We found that SCD1 was overexpressed and correlated with poor prognosis in breast cancer patients. Among a series of ICT derivatives, in vitro data showed that IC2 potentially inhibited the viability of breast cancer cells, and the mechanistic study revealed that IC2 treatment resulted in ROS activation and cellular apoptosis. We demonstrated that IC2 inhibited SCD1 activity and expression in breast cancer cells in a dose-dependent manner. Moreover, SCD1 overexpression alleviated IC2-induced cytotoxicity and apoptosis in breast cancer cells. The new ICT derivative, IC2, was developed to induce breast cancer cell apoptosis by inhibiting SCD1, which provides a basis for the development of IC2 as a potential clinical compound for breast cancer treatment.
         datePublished:2022-05-31T00:00:00Z
         dateModified:2022-05-31T00:00:00Z
         pageStart:1
         pageEnd:17
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12935-022-02621-y
         keywords:
            Cancer Research
            Cell Biology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig8_HTML.png
         isPartOf:
            name:Cancer Cell International
            issn:
               1475-2867
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Chen Yang
               affiliation:
                     name:Jiangnan University
                     address:
                        name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yi-Yuan Jin
               affiliation:
                     name:Jiangnan University
                     address:
                        name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                        type:PostalAddress
                     type:Organization
                     name:Taizhou Center for Disease Control and Prevention
                     address:
                        name:Taizhou Center for Disease Control and Prevention, Taizhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jie Mei
               affiliation:
                     name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
                     address:
                        name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
                        type:PostalAddress
                     type:Organization
                     name:Wuxi Clinical Medical College, Nanjing Medical University
                     address:
                        name:Wuxi Clinical Medical College, Nanjing Medical University, Wuxi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Die Hu
               affiliation:
                     name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering
                     address:
                        name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering, Changzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaoyu Jiao
               affiliation:
                     name:Jiangnan University
                     address:
                        name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hui-Lian Che
               affiliation:
                     name:Jiangnan University
                     address:
                        name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chun-Lei Tang
               affiliation:
                     name:Jiangnan University
                     address:
                        name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yan Zhang
               affiliation:
                     name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
                     address:
                        name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Guo-Sheng Wu
               affiliation:
                     name:Jiangnan University
                     address:
                        name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Identification of icaritin derivative IC2 as an SCD-1 inhibitor with anti-breast cancer properties through induction of cell apoptosis
      description:Breast cancer is the most common malignancy affecting women, yet effective targets and related candidate compounds for breast cancer treatment are still lacking. The lipogenic enzyme, stearoyl-CoA desaturase-1 (SCD1), has been considered a potential target for breast cancer treatment. Icaritin (ICT), a prenylflavonoid derivative from the Traditional Chinese Medicine Epimedii Herba, has been reported to exert anticancer effects in various types of cancer. The purpose of the present study was to explore the effect of the new ICT derivative, IC2, targeting SCD1 on breast cancer cells and to explore the specific mechanism. Immunohistochemistry and semiquantitative evaluation were performed to detect the expression level of SCD1 in normal and tumor samples. Computer-aided drug design (CADD) technology was used to target SCD1 by molecular docking simulation, and several new ICT derivatives were prepared by conventional chemical synthesis. Cell viability was evaluated by an MTT assay and dead cell staining. SCD1 expression in cancer cells was determined by Western blot and qRT-PCR analyses. The enzymatic activity of SCD1 was evaluated by detecting the conversion rate of [d31] palmitic acid (PA) using Gas chromatography-mass spectrometry (GC–MS). DAPI staining, flow cytometry and Western blot were used to detect cell apoptosis. Mitochondrial membrane potential and reactive oxygen species (ROS) assays were used to determine cell mitochondrial function. Lentiviral transduction was utilized to generate SCD1-overexpressing cell lines. We found that SCD1 was overexpressed and correlated with poor prognosis in breast cancer patients. Among a series of ICT derivatives, in vitro data showed that IC2 potentially inhibited the viability of breast cancer cells, and the mechanistic study revealed that IC2 treatment resulted in ROS activation and cellular apoptosis. We demonstrated that IC2 inhibited SCD1 activity and expression in breast cancer cells in a dose-dependent manner. Moreover, SCD1 overexpression alleviated IC2-induced cytotoxicity and apoptosis in breast cancer cells. The new ICT derivative, IC2, was developed to induce breast cancer cell apoptosis by inhibiting SCD1, which provides a basis for the development of IC2 as a potential clinical compound for breast cancer treatment.
      datePublished:2022-05-31T00:00:00Z
      dateModified:2022-05-31T00:00:00Z
      pageStart:1
      pageEnd:17
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12935-022-02621-y
      keywords:
         Cancer Research
         Cell Biology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12935-022-02621-y/MediaObjects/12935_2022_2621_Fig8_HTML.png
      isPartOf:
         name:Cancer Cell International
         issn:
            1475-2867
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Chen Yang
            affiliation:
                  name:Jiangnan University
                  address:
                     name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yi-Yuan Jin
            affiliation:
                  name:Jiangnan University
                  address:
                     name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                     type:PostalAddress
                  type:Organization
                  name:Taizhou Center for Disease Control and Prevention
                  address:
                     name:Taizhou Center for Disease Control and Prevention, Taizhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jie Mei
            affiliation:
                  name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
                  address:
                     name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
                     type:PostalAddress
                  type:Organization
                  name:Wuxi Clinical Medical College, Nanjing Medical University
                  address:
                     name:Wuxi Clinical Medical College, Nanjing Medical University, Wuxi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Die Hu
            affiliation:
                  name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering
                  address:
                     name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering, Changzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaoyu Jiao
            affiliation:
                  name:Jiangnan University
                  address:
                     name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hui-Lian Che
            affiliation:
                  name:Jiangnan University
                  address:
                     name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chun-Lei Tang
            affiliation:
                  name:Jiangnan University
                  address:
                     name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yan Zhang
            affiliation:
                  name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
                  address:
                     name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Guo-Sheng Wu
            affiliation:
                  name:Jiangnan University
                  address:
                     name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Cell International
      issn:
         1475-2867
      volumeNumber:22
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Jiangnan University
      address:
         name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
         type:PostalAddress
      name:Jiangnan University
      address:
         name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
         type:PostalAddress
      name:Taizhou Center for Disease Control and Prevention
      address:
         name:Taizhou Center for Disease Control and Prevention, Taizhou, China
         type:PostalAddress
      name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
      address:
         name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
         type:PostalAddress
      name:Wuxi Clinical Medical College, Nanjing Medical University
      address:
         name:Wuxi Clinical Medical College, Nanjing Medical University, Wuxi, China
         type:PostalAddress
      name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering
      address:
         name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering, Changzhou, China
         type:PostalAddress
      name:Jiangnan University
      address:
         name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
         type:PostalAddress
      name:Jiangnan University
      address:
         name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
         type:PostalAddress
      name:Jiangnan University
      address:
         name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
         type:PostalAddress
      name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
      address:
         name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
         type:PostalAddress
      name:Jiangnan University
      address:
         name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Chen Yang
      affiliation:
            name:Jiangnan University
            address:
               name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
               type:PostalAddress
            type:Organization
      name:Yi-Yuan Jin
      affiliation:
            name:Jiangnan University
            address:
               name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
               type:PostalAddress
            type:Organization
            name:Taizhou Center for Disease Control and Prevention
            address:
               name:Taizhou Center for Disease Control and Prevention, Taizhou, China
               type:PostalAddress
            type:Organization
      name:Jie Mei
      affiliation:
            name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
            address:
               name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
               type:PostalAddress
            type:Organization
            name:Wuxi Clinical Medical College, Nanjing Medical University
            address:
               name:Wuxi Clinical Medical College, Nanjing Medical University, Wuxi, China
               type:PostalAddress
            type:Organization
      name:Die Hu
      affiliation:
            name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering
            address:
               name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering, Changzhou, China
               type:PostalAddress
            type:Organization
      name:Xiaoyu Jiao
      affiliation:
            name:Jiangnan University
            address:
               name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
               type:PostalAddress
            type:Organization
      name:Hui-Lian Che
      affiliation:
            name:Jiangnan University
            address:
               name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
               type:PostalAddress
            type:Organization
      name:Chun-Lei Tang
      affiliation:
            name:Jiangnan University
            address:
               name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
               type:PostalAddress
            type:Organization
      name:Yan Zhang
      affiliation:
            name:Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University
            address:
               name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
               type:PostalAddress
            type:Organization
      name:Guo-Sheng Wu
      affiliation:
            name:Jiangnan University
            address:
               name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
      name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
      name:Taizhou Center for Disease Control and Prevention, Taizhou, China
      name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
      name:Wuxi Clinical Medical College, Nanjing Medical University, Wuxi, China
      name:Jiangsu Key Laboratory of Advanced Catalytic Materials & Technology, School of Petrochemical Engineering, Changzhou, China
      name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
      name:Wuxi School of Medicine, Jiangnan University, Wuxi, China
      name:School of Pharmaceutical Science, Jiangnan University, Wuxi, China
      name:Department of Oncology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China
      name:Wuxi School of Medicine, Jiangnan University, Wuxi, China

External Links {🔗}(175)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Isotope
  • Prism.js

CDN Services {📦}

  • Crossref

4.38s.